| Ytd | -59.24% | |
| 1y | -62.30% |
| Open | 3.26 | Prev Close | 3.28 | Low | 3.17 | High | 3.33 | Mkt Cap | 48.68M |
| Vol | 237.33K | Avg Vol | 339.09K | EPS | -3.21 | P/E | N/A | Forward P/E | -0.87 |
| Beta | -0.75 | Short Ratio | 15.72 | Inst. Own | 42.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 2.71 | 200-d Avg | 3.96 | 1yr Est | 20.00 |
CRVO News
CervoMed (NASDAQ: CRVO - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy a
CervoMed Inc. (NASDAQ: CRVO - Get Free Report) has earned a consensus recommendation of "Moderate Bu
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposu
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company fo
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (I
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (I
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnol
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementi
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo
Innovation Passport award designed to support accelerated time to market and help expedite patient a
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imag
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo
HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo
Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is
Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodeg
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global re
